Navigation Links
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Date:11/16/2007

s and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA can be used alone or in combination with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs). HUMIRA is also approved for reducing signs and symptoms in patients with active AS. In February 2007, HUMIRA was approved for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy and in reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab.

In Europe, HUMIRA, in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying anti-rheumatic drugs (DMARDs) including MTX has been inadequate, and for the treatment of severe, active and progressive RA in adults not previously treated with MTX. HUMIRA can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate. HUMIRA has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with MTX.

Also in Europe, HUMIRA is indicated for the treatment of active and progressive PsA in adults when the response to previous DMARD therapy has been inadequate and for the treatment of severe, active AS in adults who have had an inadequate response to conventional therapy. In June 2007, HUMIRA was approved in Europe for reducing the signs and symptoms and inducing and maintaining clinical remission in adults with severe active Crohn's disease, who have had an inadequate response to conventional therapy.

Abbott's Commitment to Immunology

Abbott is focused on the discovery and development o
'/>"/>

SOURCE Abbott
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)...  A novel biomarker for rheumatoid arthritis (RA) ... early-stage disease, when treatment can often arrest further ... study in The Journal of Rheumatology. ... ) and other institutions found that elevated blood-serum ... testing, including rheumatoid factor (RF) and anti-citrullinated peptide ...
(Date:8/27/2014)... August 27, 2014 “We are honored ... vendors,” said Ven Thangaraj, CEO of Radiant Sage. “We ... are taking the imaging corelab market to a different ... and research organizations to efficiently and effectively manage the ... data to be analyzed and read by trained physicians. ...
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, ... Partners, today announced the hiring of veteran equity analyst ... equity analyst. Mr. Butler will focus on the biotech/biopharma ... team a wealth of experience and a broad network ... , Senior Managing Director and Head of Equities at ...
(Date:8/27/2014)... 2014 Reportbuyer.com has added a new ... - A Rational View https://www.reportbuyer.com/product/1595336/The-Graphene-Opportunity---A-Rational-View.html ... A similar amount of hype currently surrounds ... microelectronics to water treatment, but is graphene the ... the Graphene Opportunity Report, authored by Tim ...
Breaking Biology Technology:Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... ANGELES, Oct. 20 The Cure Our Children ... today,that the U.S. Food and Drug Administration (FDA) ... unique drug product for children with,Ewing,s Sarcoma cancer. ... possible,by the generous volunteers and researchers in private ...
... Oct. 20 On Wednesday, October,22, 2008, GlaxoSmithKline plc ... results for the three months ended September 30, 2008. ... Exchange at,approximately 12:00pm UK, 7:00 am EDT., At ... global teleconference,for analysts and investors, hosted by Andrew Witty, ...
... Oct. 20 Sustainable Oils has named ... as the company,s general manager. Scott Johnson ... to build camelina,production and marketing opportunities for ... joined the company on Oct. 1., ...
Cached Biology Technology:FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 2Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 3Sustainable Oils Names Scott Johnson as General Manager, Expands Management Team for Camelina Research and Production 4
(Date:8/27/2014)... /PRNewswire-iReach/ -- The IEEE Engineering in Medicine and Biology ... International Conference (EMBC,14), this year being held at the ... Illinois , from Tuesday, August 26 through Saturday, ... industry professionals in science, medicine, and engineering are registered ... This year,s conference theme is ...
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... is available in German . ... the most common inherited disease affecting the peripheral nervous ... Max Planck Institute of Experimental Medicine and University Medical ... cells is impaired in rats with the disease. These ... known as myelin, which facilitates the rapid transfer of ...
Breaking Biology News(10 mins):Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for incurable Charcot-Marie-Tooth disease 2
... the first human clinical trial of a recombinant vaccine ... ?and the results indicate the vaccine is safe and ... Center researchers report. , The nearly year-long pilot study ... each group received a series of three injections of ...
... Medical Center have uncovered part of the genetic mechanism that ... , A team led by SFVAMC vascular surgeon Rajabrata Sarkar, ... is essential for the growth of new arteries when the ... identified and described, for the first time, the specific DNA ...
... Brookhaven National Laboratory have just launched a web-based 3-D ... a popular laboratory mouse (see http://www.bnl.gov/CTN/mouse/ ). ... extremely accurate anatomical templates and use them to map ... brain are metabolically active and where particular genes are ...
Cached Biology News:Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 2Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 3Human trial proves ricin vaccine safe, induces neutralizing antibodies; further tests planned 4Genetic key to growth of new arteries is identified 2Genetic key to growth of new arteries is identified 3
ANTI S. ENT TOX BC2D...
Porcine Serum US Origin 6 Months or Older...
... PlusOne Silver Staining Kit, Protein, ... Heukeshoven and Dernick (1), the kit ... gel electrophoresis systems.Silver Staining Kit, Protein ... of proteins in polyacrylamide gels in ...
All serum is collected from adult animals aged 6 months or older. Certified U.S. orgin. Pricing: $35/unit for 1 - 10 units...
Biology Products: